Concepedia

Kyle R. Brimacombe

KR

44

Publications

4.6K

Citations

29

H-Index

2004

Active since

Affiliations

National Institutes of Health(Current)

National Center for Advancing Translational Sciences

National Cancer Institute

Dana-Farber Cancer Institute

Massachusetts Institute of Technology

Kyle R. Brimacombe is an author at National Institutes of Health specializing in medicine, drug discovery, and pharmacology.

Top concepts

MedicinePharmacologyDrug DiscoveryBiochemistryCell BiologyNatural SciencesEngineeringHigh-throughput ScreeningBioanalysisCancer Research

Publications per year

2004–2021

44

Publications

44

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

Dimitrios Anastasiou, Yimin Yu, William J. Israelsen et al. · Nature Chemical Biology · 2012 · 804 citations · Full text

Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors

Anju Singh, Sreedhar Venkannagari, Kyu Hee Oh et al. · ACS Chemical Biology · 2016 · 587 citations

Keap1-deficient Nsclc Tumors, Small Molecule Inhibitor, Cancer Biology +21

A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate

Michael E. Pacold, Kyle R. Brimacombe, Sze Ham Chan et al. · Nature Chemical Biology · 2016 · 571 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Serine Synthesis +10

Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo

Fadi J. Najm, Mayur Madhavan, Anita Zaremba et al. · Nature · 2015 · 416 citations

Regenerative Medicine, Induced Pluripotent Stem Cell, Neuroregeneration +10

Assay Guidance Manual [Internet]

Sarine Markossian, A Grossman, Kyle R. Brimacombe et al. · 2004 · 287 citations

Pharmaceutical Research, Drug Target, Biochemistry +15

Rows per page

1–5 of 44